APOLLO Oncology Clinical Trials Program

APOLLO Oncology Clinical Trials Program

The APOLLO Oncology Clinical Trials Program is a series of trials evaluating and investigating whether Apollomics’ proprietary assets can work in concert with each other or with other agents to improve single agent immunotherapy response rates, and, ultimately, to confer clinical benefit to patients with cancer.

APOLLO Trial

APOLLO is a Phase 1/2, open label, two-arm, multi-center dose escalation and expansion study targeting locally advanced or metastatic disease.

Agents:           APL-101 (c-Met inhibitor) + APL-501 (anti-PD-1)
Phase:
            Phase 1/2
Indication:       Hepatocellular Carcinoma
Trial:               NCT03655613

Agents:           APL-101 (c-Met inhibitor) + nivolumab (anti-PD-1)
Phase:
            Phase 1/2
Indication:       Renal Cell Carcinoma
Trial:               NCT03655613

APOLLO-2 Trial

APOLLO-2 is a planned, clinical trial combining two Apollomics agents: APL-101 and APL-103.

Agents:           APL-101 (c-Met inhibitor) + ES-072 (epidermal growth factor receptor inhibitor)
Phase: 
            TBA
Indication:       TBA

Posters & Publications

Posters and Publications on our assets can be found here.